Posted by Michael Wonder on 25 Oct 2023
Daratumumab in combination with lenalidomide and dexamethasone for untreated patients with multiple myeloma who are ineligible for stem cell transplantation
25 October 2023 - NICE has published final evidence-based recommendations on the use of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone for the first-line treatment of patients with multiple myeloma who are ineligible for stem cell transplantation.
Daratumumab, when used in combination with lenalidomide and dexamethasone, is recommended as an option for the first-line treatment of adults with multiple myeloma who are ineligible for autologous stem cell transplantation. It is only recommended if Janssen provides it according to the commercial arrangement.
